Lifecare will present its Sencell Glucose Sensor development status at this year’s annual Diabetes Technology Meeting of the Diabetes Technology Society in San Francisco November 12th-14th, and November 19th.
Lifecare CSO Prof. Andreas Pfützner will present “Use of the Sencell Osmotic Pressure-Based Glucose Sensor in a Standard Needle Sensor Environment”. The presentation is a result of Lifecares successful achievements to miniaturize the Sencell Glucose Sensor to a point where it is already smaller than the initial target size. When put into a hypodermic needle, the core sensing element can be used similar to currently existing subcutaneous needle sensors with the advantage of a prolonged usage time.
“This invitation allows Lifecare to present and discuss the unique nanotechnology-driven Sencell development with leading international scientists in the field of diabetes technology.” says Lifecare CSO Prof. Andreas Pfützner.
“We are making progress with our Sencell technology and are very happy to announce the potential using our core sensing element integrated in a hypodermic needle. This positions Lifecare with additional product opportunities based on our sensor technology”, says Lifecare CEO Joacim Holter.
The Diabetes Technology Meeting is a leading international diabetes technology conference headed by Prof. David Klonoff, who is also the Chairman of Lifecare’s scientific advisory board. In addition, members of Lifecare’s scientific advisory board Prof. Lutz Heinemann and Prof. Kåre Birkeland are presenting at the Diabetes Technology Meeting, representing other institutions.
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.
For more information, please contact:
+47 40 05 90 40
Access the news on Oslo Bors NewsWeb site